Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Explore the criteria that define blue-chip altcoins and how they fit into a diversified crypto portfolio. Learn evaluation tips and common red flags.
19,751 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Pi Network confirms the long-anticipated network update finally, announcing a successful v19.6 migration and outlinin...
South Korea is accelerating its digital won experiment, moving from a controlled test to a broader rollout. This arti...
NASA slows plans for Artemis II after engineers find a helium-flow issue in the upper stage, forcing a rollback to th...
A potential 50% tariff on Canadian goods could lift construction costs and tighten loan terms. If negotiations fail, ...
A growing cohort of retirees is exploring a 5.5% withdrawal strategy as market conditions and Social Security plannin...
As Netflix stumbles, investors wonder if Disney down 2026 offers a rare contrarian opportunity. This article digs int...
A growing number of would-be investors miss Buffett’s simple path to wealth because they cannot save enough to invest...
Oklo stock surged as investors weighed its plans for advanced reactors against the fast-moving AI data-center boom. T...
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
A Berkshire-inspired ETF touts a 15% yield by layering a stock-picker approach with an option strategy and return of ...
Macerich faces a retail landscape that’s evolved in 2025. This deep dive breaks down the factors shaping macerich (ma...